STOCK TITAN

Hydreight Announces Normal Course Issuer Bid

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Hydreight (OTCQB: HYDTF; TSXV: NURS) announced a normal course issuer bid to repurchase up to 4,951,189 common shares, representing ~9.27% of issued shares and ~10.0% of the public float. The Bid runs from March 12, 2026 to March 11, 2027.

Purchases will be made on the Exchange at prevailing market prices through Research Capital Corporation and funded from existing working capital. The company said purchases aim to facilitate an orderly market and could be used if shares trade below perceived underlying value.

Loading...
Loading translation...

AI-generated analysis. Not financial advice.

Positive

  • Authorized repurchase of 4,951,189 shares (~9.27%)
  • Buyback covers up to 10.0% of public float
  • Program runs from March 12, 2026 to March 11, 2027

Negative

  • Buyback funded from existing working capital
  • Purchases at the prevailing market price could increase cash outflow

News Market Reaction – HYDTF

+2.56%
1 alert
+2.56% News Effect

On the day this news was published, HYDTF gained 2.56%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

NCIB share limit: 4,951,189 shares Outstanding share percentage: 9.27% Public float: 49,511,894 shares +3 more
6 metrics
NCIB share limit 4,951,189 shares Maximum common shares to purchase for cancellation under the Bid
Outstanding share percentage 9.27% Portion of currently outstanding common shares targeted by the Bid
Public float 49,511,894 shares Company’s public float used to calculate Bid limit
Float percentage 10.0% Portion of public float that may be repurchased under the Bid
Bid start date March 12, 2026 Commencement date of the normal course issuer bid
Bid end date March 11, 2027 Scheduled termination date of the normal course issuer bid

Market Reality Check

Price: $2.90 Vol: Volume 16,529 is 0.43x th...
low vol
$2.90 Last Close
Volume Volume 16,529 is 0.43x the 20-day average of 38,415, indicating subdued trading ahead of the news. low
Technical Shares trade below the 200-day MA, at $1.95 versus the 200-day MA of $2.54, after a -1.52% daily move.

Peers on Argus

HYDTF slipped -1.52% while key peers were mostly flat or down: MDRX -5.33%, VHIB...

HYDTF slipped -1.52% while key peers were mostly flat or down: MDRX -5.33%, VHIBF -3.04%, and others at 0%. No momentum-clustered sector move was detected.

Historical Context

5 past events · Latest: Feb 02 (Positive)
Pattern 5 events
Date Event Sentiment Move Catalyst
Feb 02 Revenue guidance & financing Positive +6.4% Issued 2026 revenue and EBITDA guidance plus a $15M bought-deal financing.
Dec 31 New product launch Positive +10.2% Entered at-home STI testing market with exclusive deal and ~50,000 pre-orders.
Dec 18 Operational milestone Positive +2.5% Surpassed 1.3M product orders and exceeded 2025 operational targets.
Dec 02 Corporate update Positive +26.2% Highlighted strong Q3 momentum, VSDHOne growth, and 2026 strategic priorities.
Nov 26 Earnings results Positive -9.8% Reported 132% YoY revenue growth and fourth consecutive profitable quarter.
Pattern Detected

Positive operational and guidance updates have usually been met with positive price reactions, with one notable divergence on strong quarterly results.

Recent Company History

Over the past several months, Hydreight has reported rapid growth and expanding initiatives. Q3 2025 results showed strong revenue growth and profitability on Nov 26 and Dec 2, followed by milestones like surpassing 1.3M product orders on Dec 18. The company then entered the at-home STI testing market with about 50,000 pre-orders on Dec 31, and issued fiscal 2026 revenue guidance of roughly $150M on Feb 2. Today’s buyback announcement follows this trajectory of scaling operations and capital deployment.

Market Pulse Summary

This announcement introduced a normal course issuer bid authorizing repurchases of up to 4,951,189 s...
Analysis

This announcement introduced a normal course issuer bid authorizing repurchases of up to 4,951,189 shares, about 9.27% of outstanding stock and 10.0% of the 49,511,894-share public float, funded from existing working capital. It follows a series of growth-oriented updates involving revenue expansion, new product lines, and rising order volumes. Investors may watch actual buyback activity, future guidance, and subsequent operational metrics to gauge how capital allocation supports the company’s growth plans.

Key Terms

normal course issuer bid, public float, tsx venture exchange, management information circular
4 terms
normal course issuer bid financial
"announces today its intention to make a normal course issuer bid (the "Bid")"
A Normal Course Issuer Bid is when a company buys back its own shares from the stock market over time. This usually shows that the company believes its stock is undervalued and wants to support its price, which can be important for investors to watch.
public float financial
"10.0% of 49,511,894 which represents the Company's Public Float"
Public float is the total number of a company's shares that are available for trading by the general public. It excludes shares held by company insiders or large stakeholders who are unlikely to sell them easily. This figure helps investors understand how much of the company's stock is actively available, which can influence its liquidity and how easily its price might change.
tsx venture exchange regulatory
"as that term is defined in the policies of the TSX Venture Exchange (the "Exchange")"
A junior stock exchange in Canada where smaller, early-stage companies list shares to raise capital and gain public visibility. Think of it as a farmers’ market for young businesses: it offers investors a chance to buy into fast-growing but higher-risk ventures, with looser listing rules and typically lower liquidity than major exchanges. It matters because performance and financing on this exchange can signal growth prospects or risk for investors.
management information circular regulatory
"include a summary of the Bid in the management information circular to be mailed"
A management information circular is a document sent to shareholders ahead of a company meeting that explains who is asking for votes, what decisions will be made, and why management recommends a particular outcome. Like an instruction booklet and argument sheet combined, it lays out details such as board nominees, executive pay, major transactions and any conflicts, helping investors decide how to vote and judge whether leadership choices could affect the company’s future value.

AI-generated analysis. Not financial advice.

LAS VEGAS and VANCOUVER, BC, March 9, 2026 /PRNewswire/ - Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6) ("Hydreight" or the "Company"), a provider of compliant digital health infrastructure and on-demand healthcare services across the United States, announces today its intention to make a normal course issuer bid (the "Bid") to purchase for cancellation, from time to time, as it considers advisable, up to 4,951,189 of its issued and outstanding common shares, being approximately 9.27% of the Company's currently outstanding common shares and approximately 10.0% of 49,511,894 which represents the Company's Public Float (as that term is defined in the policies of the TSX Venture Exchange (the "Exchange"). The Bid will commence on March 12, 2026, and will terminate on March 11, 2027, or such earlier time as the Bid is completed or at the option of the Company. Research Capital Corporation of Vancouver, British Columbia will conduct the Bid on behalf of the Company.

The Bid will be conducted in accordance with applicable securities laws and the policies of the Exchange. Purchases will be made on the open market through the facilities of the Exchange. The price which the Company will pay for any shares purchased by it will be the prevailing market price of such common shares on the Exchange at the time of such purchase. The purchase of the common shares under the Bid is being funded from existing working capital.

In accordance with Exchange policies, the Company will include a summary of the Bid in the management information circular to be mailed to shareholders of the Company in respect of its next meeting of shareholders.

The Company believes that purchases of its common shares pursuant to the Bid may contribute to the facilitation of an orderly market and is in the best interests of the Company and its shareholders. In the event that the Company believes that its common shares begin trading in a price range that does not adequately reflect their underlying value based on the Company's business prospects, growth and financial position, the Company may purchase common shares pursuant to the Bid.

Shane Madden, Chief Executive Officer of Hydreight, commented:

"Hydreight has continued to demonstrate strong operational momentum as we scale our digital health infrastructure platform across the United States. The Board believes that the current market price of the Company's shares does not fully reflect the strength of our business model, growth trajectory, and long-term opportunities. The normal course issuer bid provides us with the flexibility to allocate capital in a disciplined manner while creating additional value for our shareholders."

On behalf of the Board of Directors

Shane Madden
Director and Chief Executive Officer
Hydreight Technologies Inc.

Hydreight Technologies Inc Ranked Number 56 Fastest-Growing Company in North America on the Deloitte Technology Fast 500™

Neither the TSX Venture Exchange nor its Regulation Services Provider (as the term is defined in the Policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

About Hydreight Technologies Inc.

Hydreight Technologies Inc is building one of the largest mobile clinic networks in the United States. Its proprietary, fully integrated platform has hosted a network of over 3000 nurses, over 300 doctors and a pharmacy network through its Doctor networks across 50 states. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking, and managing patient data, which enables licensed healthcare professionals to provide services directly to patients at home, office or hotel. Hydreight is bridging the gap between provider compliance and patient convenience, empowering nurses, med spa technicians, and other licensed healthcare professionals. The Hydreight platform allows healthcare professionals to deliver services independently, on their own terms, or to add mobile services to existing location-based operations. Hydreight has a 503B pharmacy network servicing all 50 states and is closely affiliated with a U.S. certified e-script and telemedicine provider network.

About VSDHOne - Direct to Consumer Platform

Developed in partnership with Victory Square Technologies (CSE: VST) (OTC: VSQTF) (FWB: 6F6), Hydreight Technologies launched the VSDHOne (Read as VSDH-One) platform. VSDHOne simplifies the entry challenges for companies and medi-spa businesses to enter the online healthcare space compliantly. This platform will help all businesses to launch a direct-to-consumer healthcare brand in a matter of days in all 50 states. Compliant offerings include: GLP-1s, peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy, hair loss, skincare, sexual health and more. Hydreight invested in technology, legal and infrastructure to launch this platform. The VSDHOne platform offers a complete, and modular end-to-end solution for businesses looking to launch direct-to-consumer healthcare brands. From compliance and telemedicine technology to nationwide doctor and pharmacy networks, VSDHOne provides all the tools needed for a seamless entry into the online healthcare space. The platform is designed to significantly reduce the time and costs associated with launching such services, making it possible for businesses to go live in days instead of months.

Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements, including statements regarding the Bid. These statements are subject to a number of risks and uncertainties. Actual results may differ materially from results contemplated by the forward-looking statements. When relying on forward-looking statements to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and should not place undue reliance on such forward-looking statements. The Company does not undertake to update any forward looking statements, oral or written, made by itself or on its behalf, except as required by applicable law.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/hydreight-announces-normal-course-issuer-bid-302707912.html

SOURCE Hydreight Technologies Inc.

FAQ

What does Hydreight's March 9, 2026 normal course issuer bid (HYDTF) authorize?

It authorizes repurchase of up to 4,951,189 common shares, about 9.27% of issued shares. According to the company, purchases may be made on the open market through Research Capital Corporation between March 12, 2026 and March 11, 2027.

How will Hydreight (HYDTF) fund the share repurchases announced March 9, 2026?

Hydreight will fund repurchases from existing working capital. According to the company, the purchases will be executed on the Exchange at prevailing market prices and funded using the company's current cash resources rather than new financing.

What percentage of Hydreight's public float does the HYDTF buyback represent and why?

The buyback represents approximately 10.0% of the public float. According to the company, repurchases are intended to facilitate an orderly market and to address share prices that management believes may not reflect underlying business value.

When will Hydreight (HYDTF) execute purchases under the normal course issuer bid?

Purchases will occur on the Exchange from March 12, 2026 to March 11, 2027, unless completed earlier. According to the company, Research Capital Corporation will conduct open-market purchases in compliance with Exchange policies and securities laws.